Kura Oncology (KURA) PT Raised to $25.00 at Citigroup

Kura Oncology (NASDAQ:KURA) had its price objective boosted by analysts at Citigroup from $18.00 to $25.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s target price suggests a potential upside of 58.13% from the stock’s previous close.

Several other research analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Wednesday, May 8th. BidaskClub upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, May 7th. ValuEngine upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, March 27th. HC Wainwright set a $31.00 price objective on shares of Kura Oncology and gave the stock a “buy” rating in a report on Wednesday, May 8th. Finally, Oppenheimer restated a “buy” rating on shares of Kura Oncology in a report on Tuesday, March 19th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $27.83.

Shares of KURA opened at $15.81 on Friday. The firm has a market capitalization of $606.08 million, a P/E ratio of -9.19 and a beta of 2.79. Kura Oncology has a one year low of $10.20 and a one year high of $22.00. The company has a current ratio of 13.80, a quick ratio of 13.80 and a debt-to-equity ratio of 0.05.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, May 7th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. On average, research analysts expect that Kura Oncology will post -1.77 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of KURA. Fosun International Ltd acquired a new stake in shares of Kura Oncology during the 4th quarter valued at about $2,643,000. Rhumbline Advisers boosted its position in shares of Kura Oncology by 59.1% during the 4th quarter. Rhumbline Advisers now owns 37,118 shares of the company’s stock valued at $521,000 after acquiring an additional 13,781 shares in the last quarter. MetLife Investment Advisors LLC boosted its position in shares of Kura Oncology by 111.6% during the 3rd quarter. MetLife Investment Advisors LLC now owns 21,375 shares of the company’s stock valued at $374,000 after acquiring an additional 11,273 shares in the last quarter. Prosight Management LP boosted its position in shares of Kura Oncology by 24.8% during the 4th quarter. Prosight Management LP now owns 316,581 shares of the company’s stock valued at $4,445,000 after acquiring an additional 62,950 shares in the last quarter. Finally, Vanguard Group Inc boosted its position in shares of Kura Oncology by 2.1% during the 3rd quarter. Vanguard Group Inc now owns 1,455,818 shares of the company’s stock valued at $25,477,000 after acquiring an additional 29,785 shares in the last quarter. Institutional investors own 83.95% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Featured Story: Book Value Per Share – BVPS

The Fly

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.